Literature DB >> 16416224

Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.

Vijaya S Pratha1, Daniel L Hogan, James R Lane, Paul J Williams, Michael S Burton, Richard B Lynn, Robyn G Karlstadt.   

Abstract

Our objective was to compare the onset and duration of a single dose of pantoprazole or omeprazole on maximally stimulated gastric acid secretion. This double-blind, randomized, placebo-controlled study involved 36 healthy adults and utilized continuous pentagastrin infusion to stimulate acid secretion after administration of pantoprazole, 40 mg, omeprazole, 20 mg, or placebo. Gastric aspirates were collected over 24 hr and analyzed for volume, pH, and hydrogen ion concentration, and gastric acid outputs (GAO) were calculated. Comparison between GAO and intragastric pH was performed. Pantoprazole resulted in significantly greater inhibition of GAO than omeprazole. Mean cumulative 24-hr GAO was 164 +/- 130 mEq for pantoprazole versus 283 +/- 159 mEq for omeprazole (P = 0.031). Pantoprazole patients reached and maintained GAO levels below the 10-mEq/hr threshold at 5.7 hr, whereas omeprazole patients never reached this threshold. We conclude that pantoprazole significantly suppressed gastric acid secretion compared to omeprazole. Comparisons between pH and GAO showed that GAO was a more appropriate measure of gastric acid secretion than intragastric pH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416224     DOI: 10.1007/s10620-006-3096-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.

Authors:  K Nishina; K Mikawa; Y Takao; M Shiga; N Maekawa; H Obara
Journal:  Anesth Analg       Date:  2000-03       Impact factor: 5.108

Review 2.  Proton pump inhibitors and acid-related diseases.

Authors:  G Sachs
Journal:  Pharmacotherapy       Date:  1997 Jan-Feb       Impact factor: 4.705

3.  Positioning of subject and of nasogastric tube during a gastric secretion study.

Authors:  M A Hassan; M Hobsley
Journal:  Br Med J       Date:  1970-02-21

4.  Continuous intravenous pentagastrin as a stimulant of maximal gastric acid secretion.

Authors:  M C Mason; G R Giles; C G Clark
Journal:  Gut       Date:  1969-01       Impact factor: 23.059

5.  Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.

Authors:  T Lind; L Rydberg; A Kylebäck; A Jonsson; T Andersson; G Hasselgren; J Holmberg; K Röhss
Journal:  Aliment Pharmacol Ther       Date:  2000-07       Impact factor: 8.171

6.  Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.

Authors:  J R Pisegna; P Martin; W McKeand; G Ohning; J H Walsh; J Paul
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

7.  Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.

Authors:  Kerstin Röhss; Göran Hasselgren; Hans Hedenström
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

8.  Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis.

Authors:  D C Metz; W J Bochenek
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

9.  Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.

Authors:  M Hartmann; U Theiss; R Huber; R Lühmann; H Bliesath; W Wurst; P W Lücker
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

10.  Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.

Authors:  M Katashima; K Yamamoto; Y Tokuma; T Hata; Y Sawada; T Iga
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.569

View more
  4 in total

1.  Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.

Authors:  Hank S Wang; David S Oh; Ariana Anderson; Jose Nieto; Phuong Tien; Gordon Ohning; Joseph R Pisegna
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

2.  Inhibition of endogenous CO by ZnPP protects against stress-induced gastric lesion in adult male albino rats.

Authors:  Ibrahim Ibrahim; Salah El-Sayed; Selim Abdel-Hakim; Magdy Hassan; Neven Aziz
Journal:  J Physiol Biochem       Date:  2012-01-13       Impact factor: 4.158

3.  A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection.

Authors:  Hye Kyong Jeong; Chang Hwan Park; Chung Hwan Jun; Gi Hoon Lee; Hyung Il Kim; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew
Journal:  J Korean Med Sci       Date:  2007-12       Impact factor: 2.153

4.  Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis.

Authors:  Young Woon Chang; Weon Jin Ko; Chi Hyuk Oh; Yoo Min Park; Shin Ju Oh; Jung Rock Moon; Jun-Hyung Cho; Jung-Wook Kim; Jae-Young Jang
Journal:  Korean J Intern Med       Date:  2018-06-14       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.